{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:32:10Z","timestamp":1746711130444,"version":"3.40.5"},"reference-count":20,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,10,1]]},"abstract":"<jats:p>OBJECTIVE: The objective of this study was to develop a patient-reported outcome measure (Strep-PRO) for assessing symptoms of group A Streptococcus (GAS) pharyngitis from the child's point of view and to present preliminary data on its internal reliability, construct validity, and responsiveness.<\/jats:p>\n               <jats:p>METHODS: We selected 8 symptoms for inclusion in the Strep-PRO. We used the Strep-PRO to assess improvement in children who were aged 5 to 15 years and had confirmed GAS pharyngitis. Children completed the scale at study visits and as a diary at home. To evaluate internal reliability, we examined correlations between the items on the scale. To evaluate construct validity, we examined the correlation at entry between Strep-PRO scores and scores on other, previously validated measures of pain and functional status. To evaluate responsiveness, we examined the change in score from enrollment to follow-up. The correlation between the Strep-PRO score and parental assessment of symptoms was also evaluated.<\/jats:p>\n               <jats:p>RESULTS: A total of 131 children were enrolled; 113 returned completed diaries. The internal reliability of the scale was high. The magnitude of correlations between Strep-PRO scores and other measures of pain and functional status ranged from 0.39 to 0.63. The responsiveness of the Strep-PRO was very good. The overall level of agreement between child Strep-PRO scores and parental assessment of symptoms was 0.57.<\/jats:p>\n               <jats:p>CONCLUSIONS: The scale seems to measure effectively both pain and overall functional status in children with GAS pharyngitis. These data support the use of Strep-PRO as a measure of outcome in future clinical trials.<\/jats:p>","DOI":"10.1542\/peds.2009-0331","type":"journal-article","created":{"date-parts":[[2009,9,28]],"date-time":"2009-09-28T11:32:40Z","timestamp":1254137560000},"page":"e557-e563","source":"Crossref","is-referenced-by-count":6,"title":["Development of a Patient-Reported Outcome Measure for Children With Streptococcal Pharyngitis"],"prefix":"10.1542","volume":"124","author":[{"given":"Nader","family":"Shaikh","sequence":"first","affiliation":[{"name":"Divisions of General Academic Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith M.","family":"Martin","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet R.","family":"Casey","sequence":"additional","affiliation":[{"name":"Rochester General Research Institute, Pediatric Infectious Diseases, Rochester, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Pichichero","sequence":"additional","affiliation":[{"name":"Rochester General Research Institute, Pediatric Infectious Diseases, Rochester, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen R.","family":"Wald","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Kathleen","family":"Colborn","sequence":"additional","affiliation":[{"name":"Divisions of General Academic Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Gerber","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana H.","family":"Kearney","sequence":"additional","affiliation":[{"name":"Divisions of General Academic Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy L.","family":"Balentine","sequence":"additional","affiliation":[{"name":"Divisions of General Academic Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ann","family":"Haralam","sequence":"additional","affiliation":[{"name":"Divisions of General Academic Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Hoberman","sequence":"additional","affiliation":[{"name":"Divisions of General Academic Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2009,10,1]]},"reference":[{"key":"2021120905040028600_R1","doi-asserted-by":"crossref","unstructured":"Powers JH. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials. Pharmacotherapy.\u20082005;25(12 pt 2):109S\u2013123S","DOI":"10.1592\/phco.2005.25.12part2.109S"},{"key":"2021120905040028600_R2","doi-asserted-by":"crossref","unstructured":"Guidance for industry: patient-reported outcome measures\u2014use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes.\u20082006;4:79","DOI":"10.1186\/1477-7525-4-79"},{"key":"2021120905040028600_R3","doi-asserted-by":"crossref","unstructured":"Varni JW, Limbers CA, Burwinkle TM. How young can children reliably and validly self-report their health-related quality of life? An analysis of 8,591 children across age subgroups with the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes.\u20082007;5:1","DOI":"10.1186\/1477-7525-5-1"},{"key":"2021120905040028600_R4","doi-asserted-by":"crossref","unstructured":"Bennike T, Brochner-Mortensen K, Kjaer E, Skadhauge K, Trolle E. Penicillin therapy in acute tonsillitis, phlegmonous tonsillitis and ulcerative tonsillitis. Acta Med Scand.\u20081951;139(4):253\u2013274","DOI":"10.1111\/j.0954-6820.1951.tb17166.x"},{"key":"2021120905040028600_R5","doi-asserted-by":"crossref","unstructured":"el-Daher NT, Hijazi SS, Rawashdeh NM, al-Khalil IA, Abu-Ektaish FM, Abdel-Latif DI. Immediate vs. delayed treatment of group A beta-hemolytic streptococcal pharyngitis with penicillin V. Pediatr Infect Dis J.\u20081991;10(2):126\u2013130","DOI":"10.1097\/00006454-199102000-00010"},{"key":"2021120905040028600_R6","doi-asserted-by":"crossref","unstructured":"Krober MS, Bass JW, Michels GN. Streptococcal pharyngitis: placebo-controlled double-blind evaluation of clinical response to penicillin therapy. JAMA.\u20081985;253(9):1271\u20131274","DOI":"10.1001\/jama.253.9.1271"},{"key":"2021120905040028600_R7","doi-asserted-by":"crossref","unstructured":"Nelson JD. The effect of penicillin therapy on the symptoms and signs of streptococcal pharyngitis. Pediatr Infect Dis.\u20081984;3(1):10\u201313","DOI":"10.1097\/00006454-198401000-00004"},{"key":"2021120905040028600_R8","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Disney FA, Talpey WB, et al. Adverse and beneficial effects of immediate treatment of group A beta-hemolytic streptococcal pharyngitis with penicillin. Pediatr Infect Dis J.\u20081987;6(7):635\u2013643","DOI":"10.1097\/00006454-198707000-00004"},{"key":"2021120905040028600_R9","doi-asserted-by":"crossref","unstructured":"Randolph MF, Gerber MA, DeMeo KK, Wright L. Effect of antibiotic therapy on the clinical course of streptococcal pharyngitis. J Pediatr.\u20081985;106(6):870\u2013875","DOI":"10.1016\/S0022-3476(85)80228-6"},{"key":"2021120905040028600_R10","doi-asserted-by":"crossref","unstructured":"Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy.\u20081991;21(1):77\u201383","DOI":"10.1111\/j.1365-2222.1991.tb00807.x"},{"key":"2021120905040028600_R11","doi-asserted-by":"crossref","unstructured":"Shaikh N, Hoberman A, Paradise JL, et al. Responsiveness and construct validity of a symptom scale for acute otitis media. Pediatr Infect Dis J.\u20082009;28(1):9\u201312","DOI":"10.1097\/INF.0b013e318185a3a0"},{"key":"2021120905040028600_R12","doi-asserted-by":"crossref","unstructured":"Shaikh N, Hoberman A, Paradise JL, et al. Development and preliminary evaluation of a parent-reported outcome instrument for clinical trials in acute otitis media. Pediatr Infect Dis J.\u20082009;28(1):5\u20138","DOI":"10.1097\/INF.0b013e318185a387"},{"key":"2021120905040028600_R13","doi-asserted-by":"crossref","unstructured":"Bieri D, Reeve RA, Champion GD, Addicoat L, Ziegler JB. The Faces pain scale for the self-assessment of the severity of pain experienced by children: development, initial validation, and preliminary investigation for ratio scale properties. Pain.\u20081990;41(2):139\u2013150","DOI":"10.1016\/0304-3959(90)90018-9"},{"key":"2021120905040028600_R14","doi-asserted-by":"crossref","unstructured":"Stein RE, Jessop DJ. Functional Status II(R): a measure of child health status. Med Care.\u20081990;28(11):1041\u20131055","DOI":"10.1097\/00005650-199011000-00006"},{"key":"2021120905040028600_R15","doi-asserted-by":"crossref","unstructured":"Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis.\u20081987;40(2):171\u2013178","DOI":"10.1016\/0021-9681(87)90069-5"},{"key":"2021120905040028600_R16","doi-asserted-by":"crossref","unstructured":"Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures: statistics and strategies for evaluation. Control Clin Trials.\u20081991;12(4 suppl):142S\u2013158S","DOI":"10.1016\/S0197-2456(05)80019-4"},{"key":"2021120905040028600_R17","unstructured":"Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. CMAJ.\u20081986;134(8):889\u2013895"},{"key":"2021120905040028600_R18","doi-asserted-by":"crossref","unstructured":"Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol.\u20081994;47(1):81\u201387","DOI":"10.1016\/0895-4356(94)90036-1"},{"key":"2021120905040028600_R19","doi-asserted-by":"crossref","unstructured":"Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials.\u20081989;10(4):407\u2013415","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"2021120905040028600_R20","doi-asserted-by":"crossref","unstructured":"Revicki DA, Cella D, Hays RD, Sloan JA, Lenderking WR, Aaronson NK. Responsiveness and minimal important differences for patient reported outcomes. Health Qual Life Outcomes.\u20082006;4:70","DOI":"10.1186\/1477-7525-4-70"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/124\/4\/e557\/1011594\/zpe0100900e557.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/124\/4\/e557\/1011594\/zpe0100900e557.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T22:15:10Z","timestamp":1639088110000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/124\/4\/e557\/71794\/Development-of-a-Patient-Reported-Outcome-Measure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,1]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,10,1]]},"published-print":{"date-parts":[[2009,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2009-0331","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2009,10,1]]}}}